Drug Profile
Interferon alpha sublingual - Biolingus
Alternative Names: BL SLIT IILatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Biolingus
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Influenza virus infections
Most Recent Events
- 22 Sep 2020 Interferon alpha - Biolingus is available for licensing as of 22 Sep 2020. http://www.biolingus.ch/index.html#partners
- 15 Sep 2020 Preclinical trials in COVID-2019 infections (Prevention) in Switzerland (Sublingual) prior to September 2020 (Biolingus pipeline, September 2020)
- 15 Sep 2020 Preclinical trials in Influenza virus infections (Prevention) in Switzerland (Sublingual) prior to September 2020 (Biolingus pipeline, September 2020)